Global Long-Acting Monoclonal Antibodies Market Size study, by Source Type (Murine, Chimeric, Humanized, Human) by Indication (Cancer, Autoimmune Disease, inflammatory Disease, Infectious Disease, others) by End User (Hospitals Pharmacies, Drugs Stores, Retail Pharmacies, E- Commerce) and Regional Forecasts 2021-2027
- BIZ4728663
- 200 Pages
- December 2021
- Pharmaceuticals
Global Long-Acting Monoclonal Antibodies Market is valued approximately USD XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2021-2027. Long-Acting antibodies are natural antibodies and have the potential to treat and prevent disease progression in patients already infected with the virus, as well as to be given as a preventative intervention prior to exposure to the virus. The market is mainly driven by Growing therapeutic monoclonal antibody market and Current Pandemic situation of Covid-19. According to PubMed.gov the global therapeutic monoclonal antibody market was valued at approximately USD 115.2 billion in 2018 and generated revenue of USD 150 billion by the end of 2019 and is expected to generate USD 300 billion by 2025. Also, increasing rate of chronic diseases across the world is likely to increase the market growth during the forecast period. However, high manufacturing costs impedes the growth of the market over the forecast period of 2021-2027.
The key regions considered for the global Long-Acting Monoclonal Antibodies market study includes Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to presence of major players and ongoing clinical trials makes U.S. the leading player in the market. Also, North America is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2021-2027. Factors such as well-developed health infrastructure, in terms of disease treatment rate would create lucrative growth prospects for the Long-Acting Monoclonal Antibodies market across Asia-Pacific region.
Major market player included in this report are:
Eli Lilly
Abbott Laboratories
AstraZeneca plc.
Amgen Inc.
Bayer AG
Johnson & Johnson
Pfizer
GlaxoSmithKline Plc.
Merck & Co. Inc.
Novartis
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Source offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Source Type:
Murine
Chimeric
Humanized
Human
By Indication:
Cancer
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Others
By End User:
Hospitals Pharmacies
Drug Stores
Retail Pharmacies
E-commerce
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019
Base year – 2020
Forecast period – 2021 to 2027
Target Audience of the Global Long-Acting Monoclonal Antibodies Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. 1.2.1. Long-Acting Monoclonal Antibodies Market, by Region, 2019-2027 (USD Billion)
1.2.2. 1.2.1. Long-Acting Monoclonal Antibodies Market, by Source Type, 2019-2027 (USD Billion)
1.2.3. 1.2.1. Long-Acting Monoclonal Antibodies Market, by Indication, 2019-2027 (USD Billion)
1.2.4. 1.2.1. Long-Acting Monoclonal Antibodies Market, by End User, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global 1.2.1. Long-Acting Monoclonal Antibodies Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global 1.2.1. Long-Acting Monoclonal Antibodies Market Dynamics
3.1. 1.2.1. Long-Acting Monoclonal Antibodies Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Growing therapeutic monoclonal antibody market
3.1.1.2. Current Pandemic situation of Covid-19
3.1.2. Market Challenges
3.1.2.1. High Manufacturing cost
3.1.3. Market Opportunities
3.1.3.1. Rapid growth of chronic diseases
Chapter 4. Global 1.2.1. Long-Acting Monoclonal Antibodies Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
4.5. Top investment opportunity
4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1.1. Assessment of the overall impact of COVID-19 on the industry
5.1.2. Pre COVID-19 and post COVID-19 market scenario
Chapter 6. Global 1.2.1. Long-Acting Monoclonal Antibodies Market, by Source Type
6.1. Market Snapshot
6.2. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by Source Type, Performance - Potential Analysis
6.3. Global 1.2.1. Long-Acting Monoclonal Antibodies Market Estimates & Forecasts by Source Type 2018-2027 (USD Billion)
6.4. 1.2.1. Long-Acting Monoclonal Antibodies Market, Sub Segment Analysis
6.4.1. Murine
6.4.2. Chimeric
6.4.3. Humanized
6.4.4. Human
Chapter 7. Global 1.2.1. Long-Acting Monoclonal Antibodies Market, by Indication
7.1. Market Snapshot
7.2. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by Indication, Performance - Potential Analysis
7.3. Global 1.2.1. Long-Acting Monoclonal Antibodies Market Estimates & Forecasts by Indication 2018-2027 (USD Billion)
7.4. 1.2.1. Long-Acting Monoclonal Antibodies Market, Sub Segment Analysis
7.4.1. Cancer
7.4.2. Autoimmune Diseases
7.4.3. Inflammatory Diseases
7.4.4. Infectious Diseases
7.4.5. Others
Chapter 8. Global 1.2.1. Long-Acting Monoclonal Antibodies Market, by End User
8.1. Market Snapshot
8.2. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by End User, Performance - Potential Analysis
8.3. Global 1.2.1. Long-Acting Monoclonal Antibodies Market Estimates & Forecasts by End User 2018-2027 (USD Billion)
8.4. 1.2.1. Long-Acting Monoclonal Antibodies Market, Sub Segment Analysis
8.4.1. Hospitals Pharmacies
8.4.2. Drug Stores
8.4.3. Retail Pharmacies
8.4.4. E-commerce
Chapter 9. Global 1.2.1. Long-Acting Monoclonal Antibodies Market, Regional Analysis
9.1. 1.2.1. Long-Acting Monoclonal Antibodies Market, Regional Market Snapshot
9.2. North America 1.2.1. Long-Acting Monoclonal Antibodies Market
9.2.1. U.S. 1.2.1. Long-Acting Monoclonal Antibodies Market
9.2.1.1. Source Type breakdown estimates & forecasts, 2018-2027
9.2.1.2. Indication breakdown estimates & forecasts, 2018-2027
9.2.1.3. End User breakdown estimates & forecasts, 2018-2027
9.2.2. Canada 1.2.1. Long-Acting Monoclonal Antibodies Market
9.3. Europe 1.2.1. Long-Acting Monoclonal Antibodies Market Snapshot
9.3.1. U.K. 1.2.1. Long-Acting Monoclonal Antibodies Market
9.3.2. Germany 1.2.1. Long-Acting Monoclonal Antibodies Market
9.3.3. France 1.2.1. Long-Acting Monoclonal Antibodies Market
9.3.4. Spain 1.2.1. Long-Acting Monoclonal Antibodies Market
9.3.5. Italy 1.2.1. Long-Acting Monoclonal Antibodies Market
9.3.6. Rest of Europe 1.2.1. Long-Acting Monoclonal Antibodies Market
9.4. Asia-Pacific 1.2.1. Long-Acting Monoclonal Antibodies Market Snapshot
9.4.1. China 1.2.1. Long-Acting Monoclonal Antibodies Market
9.4.2. India 1.2.1. Long-Acting Monoclonal Antibodies Market
9.4.3. Japan 1.2.1. Long-Acting Monoclonal Antibodies Market
9.4.4. Australia 1.2.1. Long-Acting Monoclonal Antibodies Market
9.4.5. South Korea 1.2.1. Long-Acting Monoclonal Antibodies Market
9.4.6. Rest of Asia Pacific 1.2.1. Long-Acting Monoclonal Antibodies Market
9.5. Latin America 1.2.1. Long-Acting Monoclonal Antibodies Market Snapshot
9.5.1. Brazil 1.2.1. Long-Acting Monoclonal Antibodies Market
9.5.2. Mexico 1.2.1. Long-Acting Monoclonal Antibodies Market
9.6. Rest of The World 1.2.1. Long-Acting Monoclonal Antibodies Market
Chapter 10. Competitive Intelligence
10.1. Top Market Strategies
10.2. Company Profiles
10.2.1. Eli Lilly
10.2.1.1. Key Information
10.2.1.2. Overview
10.2.1.3. Financial (Subject to Data Availability)
10.2.1.4. Product Summary
10.2.1.5. Recent Developments
10.2.2. Abbott Laboratories
10.2.3. AstraZeneca plc
10.2.4. Amgen Inc.
10.2.5. Bayer AG
10.2.6. Johnson & Johnson
10.2.7. Pfizer
10.2.8. GlaxoSmithKline Plc.
10.2.9. Merck & Co. Inc.
10.2.10. Novartis
10.2.11. Research Process
10.3. Research Process
10.3.1. Data Mining
10.3.2. Analysis
10.3.3. Market Estimation
10.3.4. Validation
10.3.5. Publishing
10.4. Research Attributes
10.5. Research Assumption
TABLE 1. Global 1.2.1. Long-Acting Monoclonal Antibodies Market, report scope
TABLE 2. Global 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by Region 2018-2027 (USD Billion)
TABLE 3. Global 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by Source Type 2018-2027 (USD Billion)
TABLE 4. Global 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by Indication 2018-2027 (USD Billion)
TABLE 5. Global 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by End User 2018-2027 (USD Billion)
TABLE 6. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 7. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by region, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 8. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 9. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by region, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 10. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 11. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by region, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 12. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 13. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by region, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 14. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 15. Global 1.2.1. Long-Acting Monoclonal Antibodies Market by region, estimates & forecasts, 2018-2027 (USD Billion)
TABLE 16. U.S. 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 17. U.S. 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 18. U.S. 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 19. Canada 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 20. Canada 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 21. Canada 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 22. UK 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 23. UK 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 24. UK 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 25. Germany 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 26. Germany 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 27. Germany 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 28. RoE 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 29. RoE 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 30. RoE 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 31. China 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 32. China 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 33. China 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 34. India 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 35. India 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 36. India 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 37. Japan 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 38. Japan 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 39. Japan 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 40. RoAPAC 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 41. RoAPAC 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 42. RoAPAC 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 43. Brazil 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 44. Brazil 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 45. Brazil 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 46. Mexico 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 47. Mexico 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 48. Mexico 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 49. RoLA 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 50. RoLA 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 51. RoLA 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 52. Row 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts, 2018-2027 (USD Billion)
TABLE 53. Row 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 54. Row 1.2.1. Long-Acting Monoclonal Antibodies Market estimates & forecasts by segment 2018-2027 (USD Billion)
TABLE 55. List of secondary sources, used in the study of global 1.2.1. Long-Acting Monoclonal Antibodies Market
TABLE 56. List of primary sources, used in the study of global 1.2.1. Long-Acting Monoclonal Antibodies Market
TABLE 57. Years considered for the study
TABLE 58. Exchange rates considered
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
